Glaukos Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Glaukos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View analyst ratings for Glaukos or view top-rated stocks.

9 Wall Street research analysts have issued 1 year target prices for Glaukos' stock. Their GKOS stock forecasts range from $34.00 to $105.00. On average, they predict Glaukos' stock price to reach $58.56 in the next twelve months. This suggests a possible upside of 28.0% from the stock's current price.
View analysts' price targets for Glaukos or view top-rated stocks among Wall Street analysts.

Glaukos' stock was trading at $44.44 at the beginning of the year. Since then, GKOS shares have increased by 2.9% and is now trading at $45.74.
View the best growth stocks for 2022 here.

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Glaukos.

Glaukos Co. (NYSE:GKOS) issued its quarterly earnings data on Wednesday, May, 4th. The medical instruments supplier reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.14. The medical instruments supplier had revenue of $67.70 million for the quarter, compared to analysts' expectations of $60.85 million. Glaukos had a negative net margin of 9.45% and a negative trailing twelve-month return on equity of 7.95%. Glaukos's revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.21) EPS.
View Glaukos' earnings history.

Glaukos issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $270.00 million-$275.00 million, compared to the consensus revenue estimate of $270.49 million.

10 employees have rated Glaukos CEO Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among Glaukos' employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Glaukos include NovoCure (NVCR), ShockWave Medical (SWAV), Globus Medical (GMED), Inspire Medical Systems (INSP), Penumbra (PEN), Integra LifeSciences (IART), ICU Medical (ICUI), Tandem Diabetes Care (TNDM), Inari Medical (NARI), iRhythm Technologies (IRTC), Haemonetics (HAE), Merit Medical Systems (MMSI), Axonics (AXNX), NuVasive (NUVA) and Beauty Health (SKIN).
View all of GKOS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.02%), Wellington Management Group LLP (9.93%), State Street Corp (3.55%), Riverbridge Partners LLC (1.35%), Polar Asset Management Partners Inc. (1.21%) and Northern Trust Corp (1.15%). Company insiders that own Glaukos stock include Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos.

GKOS stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Renaissance Technologies LLC, Assenagon Asset Management S.A., Rhenman & Partners Asset Management AB, Exchange Traded Concepts LLC, Goldman Sachs Group Inc., Connor Clark & Lunn Investment Management Ltd., and Northern Trust Corp. Company insiders that have sold Glaukos company stock in the last two years include Joseph E Gilliam, and William J Phd Link.
View insider buying and selling activity for Glaukos or view top insider-selling stocks.

GKOS stock was bought by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., Dimensional Fund Advisors LP, Vanguard Group Inc., Citigroup Inc., Riverbridge Partners LLC, Jane Street Group LLC, Essex Investment Management Co. LLC, and Bank of America Corp DE.
View insider buying and selling activity for Glaukos or or view top insider-buying stocks.

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GKOS stock can currently be purchased for approximately $45.74.

Glaukos (NYSE:GKOS) has a market capitalization of $2.17 billion and generates $294.01 million in revenue each year. The medical instruments supplier earns $-49.59 million in net income (profit) each year or ($0.610010) on an earnings per share basis.

Glaukos employs 727 workers across the globe.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for Glaukos is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at [email protected], or via fax at 949-367-9984.